4'-hydroxydesazadesferrithiocin

structure in first source

Also Known As:

4,5-dihydro-2-(2,4-dihydroxyphenyl)-4-methylthiazole-4-carboxylic acid; 4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methylthiazole-4-carboxylic acid; deferitrin

Networked: 3 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Carboxylic Acids: 973
  - 4'-hydroxydesazadesferrithiocin: 3
- Sulfur Compounds: 278
  - Thiazoles: 392
    - 4'-hydroxydesazadesferrithiocin: 3
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Thiazoles: 392
      - 4'-hydroxydesazadesferrithiocin: 3

Experts

1.	Barton, James C: 2 articles (07/2007 - 04/2007)
2.	Bree, Mark: 1 article (01/2005)
3.	Dagher, Rafif: 1 article (01/2005)
4.	Donovan, Joanne M: 1 article (01/2005)
5.	Marquis, Judith: 1 article (01/2005)
6.	Plone, Melissa: 1 article (01/2005)

Related Diseases

1.	Iron Overload 07/01/2007 - "Drug evaluation: Deferitrin for iron overload disorders." 04/01/2007 - "Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders." 07/01/2007 - "The author concludes that deferitrin may be useful as chelation monotherapy or as part of combination or doublet chelation therapy for the treatment of severe iron overload in patients with beta-thalassemia major if its favorable pharmacokinetic profile, efficacy, safety and tolerability are confirmed in more extensive clinical trials. " 04/01/2007 - "The author concludes that deferitrin may be useful as chelation monotherapy or as part of combination or doublet chelation therapy for the treatment of severe iron overload in patients with beta-thalassemia major if its favorable pharmacokinetic profile, efficacy, safety and tolerability are confirmed in more extensive clinical trials. " 01/01/2005 - "Deferitrin, a novel, orally available iron chelator, is in the early stage of clinical development for the treatment of chronic iron overload due to transfusional therapy. "
2.	beta-Thalassemia (Cooley's Anemia) 07/01/2007 - "The author concludes that deferitrin may be useful as chelation monotherapy or as part of combination or doublet chelation therapy for the treatment of severe iron overload in patients with beta-thalassemia major if its favorable pharmacokinetic profile, efficacy, safety and tolerability are confirmed in more extensive clinical trials. " 04/01/2007 - "The author concludes that deferitrin may be useful as chelation monotherapy or as part of combination or doublet chelation therapy for the treatment of severe iron overload in patients with beta-thalassemia major if its favorable pharmacokinetic profile, efficacy, safety and tolerability are confirmed in more extensive clinical trials. " 04/01/2007 - "In phase I trials in adults with beta-thalassemia, deferitrin promoted iron excretion in a dose-related manner and was well tolerated as both a liquid and capsule in fed and fasted states. " 07/01/2007 - "In phase I clinical trials in adults with beta-thalassemia, deferitrin promoted iron excretion in a dose-related manner and was well tolerated as both a liquid and capsule in fed and fasted states. "

Related Drugs and Biologics

1.	Iron
2.	Capsules (Microcapsules)
3.	Chelating Agents

Related Therapies and Procedures

1.	Chelation Therapy (Therapy, Chelation)
2.	Therapeutics